Cisplatin is one of the most important anticancer drugs in chemotherapy of the last few years. This drug is mainly active against testicular and ovarian neoplasms, and has also been used with some success against tumours of the lung, bladder, cervix, head and neck (Rozencweig et al., 1977) . However, severe side effects such as nausea, vomiting, nephrotoxicity and neurotoxicity have been found to accompany the administration of the drug (Von Hoff et al., 1979; Krakoff, 1979) . In particular, the dose-limiting factor of cisplatin depends on its nephrotoxicity-inducing activity (Krakoff, 1979) . For this reason, development of cisplatin anologs with less nephrotoxicity-inducing activity has been attempted (Burchenal et al., 1979; Connors et al., 1979; Prestayko et al., 1979; Lelieveld et al., 1984) . At present, carboplatin, one of such analogs, is available in the clinic.
A new platinum complex, 2-aminomethylpyrrolidine (1, 1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114), has been demonstrated to have pronounced antitumour effects against various rodent tumours, and has proved to be less toxic in the kidney than cisplatin (Endoh et al., 1989) . Subsequently, it has been clarified that DWA2114 still has slightly increased urinary protein and sugar as indicators for nephrotoxicity in mice (unpublished data). There are two enantiomeric isomers, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) and (+)-(S)-2-aminomethylpyrrolidine (1, 1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114S) (Figure 1 ), since DWA2114 contains an asymmetric carbon in its carrier ligand. In general, it is well known that stereo or enantiomeric isomers exhibit different effects (Zimmerman & Feldman, 1981) . With regard to platinum complexes, Kidani et al. (1978) Pt determination Pt concentrations in plasma and tissues were determined by a modified method of Pera & Harder (1977) . Briefly, plasma and tissue samples were lyophilised and mixed with concentrated HNO3. In the case of cell pellets, they were directly mixed with concentrated HNO3. They were digested in a hot block bath, then evaporated until dry. Each residue was solubilised in 0.1 N HNO3 and estimated for Pt by flameless atomic absorption spectrophotometry using an atomic absorption spectrophotometer model AA-8500 MK II (Nippon Jarrell-Ash Co. Ltd., Kyoto, Japan) or IL Video 12 (Allied Analytical Systems, MA, USA) equipped with a heated graphite furnace.
Results

Antitumour effect
The antitumour effects of the isomers against L1210 leukaemia are shown in Table I In addition, the antitumour effect of DWA2114R against L1210 leukaemia was compared with those of cisplatin and carboplatin at 1/2LD,0 (Table III) . Cisplatin was the most active and certain cisplatin-treated mice were observed to survive for a long term. DWA2114R was more effective compared with carboplatin.
Nephrotoxicity
The nephrotoxicity-inducing activities of the isomers were analysed using BDF, mice. Table IV shows BUN values on day 3 and 5 after drug administration. BUN levels of mice treated with DWA2114R at a dose of 100 mg kg-' were not different from those of the normal mice. Toxic death was observed in the group treated with DWA2114R at 120 mg kg-' and the BUN level of one surviving mouse increased slightly on day 5. On the other hand, BUN levels slightly but significantly increased on day 3 and severely increased on day 5 in the treated group with DWA2114S at doses of 70-80 mg kg-' and toxic death was observed at 80 mg kg-'. Figure 2 shows time-dependent changes in protein and sugar levels detected in the urine. In the DWA2114S-treated mice, urinary protein and sugar increased on either day 2 or 3 at doses of more than 60 mg kg-'.
While, there was no increase in urinary protein and sugar even at 120 mg kg-' in the DWA2114R-treated mice.
Pt concentrations in plasma and tissues To account for the difference in nephrotoxicity-inducing activities between the isomers, Pt concentrations in plasma and a few selected tissues were determined at 2 h following i.p. injection of DWA2114R or DWA2114S at a dose of 80 mg kg-' in BDF, mice (Figure 3) . At 2 h after an administration of DWA2114S, the kidney had the highest concentration of Pt (88.1 jgg-1 tissue wet weight), compared with liver, spleen, lung, heart, or plasma. However, in the tissues of DWA2114R-treated mice, the highest Pt level was observed in the liver at 2 h after administration (19.1 jgg-' tissue wet weight). Pt concentration in the kidney was 16.5 ig g-' tissue wet weight also at 2 h after administration, and this was somewhat lower than that in the liver of DWA21 R-treated mice.
Pt levels of all the tissues and plasma were higher in DWA2114S-treated mice than in DWA2114R-treated mice. In particular, renal Pt concentration in the DWA2114S-treated group was more than 5-fold that in the DWA2114R-treated group. As shown in Figure 4 , a similar marked difference between renal Pt levels of the mice treated with the isomers was observed at 24 h and even 7 days after administration. On the other hand, in the liver, lung, spleen, heart, and plasma, Pt concentrations in DWA2114S-treated mice were less than 3-fold those in the corresponding tissues and plasma of DWA2114R-treated mice. Figure 5a shows Pt fold that of DWA2114R-treated mice ( Figure Sb ). An additional experiment on tissue distribution in rats was performed to examine whether the difference in tissue distribution was also observed in (1) other species and (2) i.v. administration of the isomers. A similar difference in tissue distribution was observed in rats treated i.v. with the drugs at 40 mg kg-' (Figure 6 ). Renal Pt content in kidney 2 h after injection of DWA2114S was 3.8-fold higher compared to that of DWA2114R. Tissue Figure 3 Pt concentrations of tissues and plasma 2 h after i.p. injection of DWA2114R and DWA2114S (80mg kg-') in BDF, mice. The number of mice was two (DWA21 14R) or three (DWA2114S). Bars, s.e., DWA2114R; M DWA2114S.
Drug uptake
To account for the difference between the isomers in Pt accumulation in tissues, a study of uptake of the drugs into cells was performed in vitro. Two normal rat kidney cell lines NRK49F and NRK52E, and normal rat splenocyte were exposed to 501 M of the drug at 37C for 2 h. DWA21 14S-treated cells contained much more Pt (1.5-3 fold) compared to DWA2114R (Table V) . This difference was more distinct in NRK cells than in splenocytes. Dose (mg kg-') Figure 5 Pt concentrations of kidney a, and plasma b, 2 h after i.p. injection of DWA2114R and DWA2114S (60-120 mg kg-') in BDF, mice. The number of mice was three except in the columns of DWA2114R lOOmgkg-' and DWA2114S 80mg kg-' (n=2). Bars, s.e. DWA2114R; 1 DWA2114S.
Discussion
In the antitumour experiments, both isomers showed marked antitumour effects against the murine tumours. DWA2114S was slightly more active than DWA21 14R against L1210 and Colon 26 tumours at the same dose. In contrast to the antitumour effects, the isomers showed different effects on the kidney. Bodenner et al. (1986) have reported that the peak BUN value in mice treated i.p. with cisplatin at MTD was more than 5-fold that in the normal control. We also found in this study that the increase in BUN (4-fold) was observed on day 5 after administration of DWA21 14S 70-80mg kg-'. In the mice treated with DWA2114S at 60mgkg-', the increase in BUN level was not observed but urinary protein and sugar had already injection of DWA2114R and DWA2114S (40 mg kg-') in SD rats.
The number of rats was three. Bars, s.e. =l DWA2114R; M DWA2114S. increased. On the other hand, no increases in BUN or urinary protein and sugar were observed in the mice treated with DWA2114R even at 100mg kg-'. It is worthy of mention that each isomer has a different effect on the kidney and that DWA2114R showed no nephrotoxicity, in contrast to DWA21 14S. The main tissue which accumulates Pt in cisplatin-treated animals is the kidney (Litterst et al., 1976) . In the case of DWA2114S, tissue distribution was similar to that of cisplatin and the highest Pt concentration was also found in the kidney. However, the kidney of DWA2114R-treated mice contained a much lower Pt concentration than that of DWA2114S-treated mice. In the experiments using cisplatintreated animals (Cvitkovic et al., 1977; Ward et al., 1977; Osman et al., 1984) , it has been observed that the severity of renal toxicity correlates with renal Pt concentration and that coadministration of cisplatin and diuretics causes decreases in renal Pt concentration and in BUN. Those results indicate that the high content of Pt in the kidney causes nephrotoxicity with the increase in BUN. Therefore, the fact that there was no increase of BUN in DWA2114R-treated mice could have been brought about by the low content of Pt in the kidney, and this also might explain the reason why there were no side effects of DWA2114R in the kidney. Furthermore, the difference in accumulation of Pt in the kidney was also observed in rats treated with the drugs given by i.v. administration the way platinum complexes have been clinically used. Since this difference was not dependent on an administration route of the drugs or species, DWA2114R is expected to show no nephrotoxicity in humans.
The results of drug uptake into normal kidney cells and splenocytes indicate that it was easier for DWA2114S to accumulate in the cell than it was for DWA21 14R. The results that the difference in uptake of the isomers was more distinct in the kidney cells and that drug uptake in the kidney cells was higher than in the splenocytes are consistent with the results of tissue distribution in vivo. This difference between the isomers in uptake into the cell is probably one reason for the difference in tissue distribution. It is interesting why the isomers showed different accumulation in the cell, especially in the kidney cell. We have found no difference between the isomers in binding activities to DNA or plasma protein in vitro (data not shown). One possible explanation is that it may be easier for DWA2114S to enter the cells than for DWA2114R. There have been many instances in which membrane transport is different between stereo or enantiomeric isomers requiring a carrier molecule for transport into the cell (Zimmerman & Feldman, 1981) . For instance, some anticancer agents, such as nitrogen mustard and melphalan, are known to be transported into the cell by membrane carriers (Goldenberg et al., 1970; Vistica et al., 1978) . Byfield & Calabro-Jones (1981) showed that the uptake of cisplatin also seemed to depend on a membrane transport mechanism. If we assume that the uptake of DWA21 14R and DWA2114S to the cell depends on a membrane carrier, it is possible that the isomers interact differently with a membrane carrier so that a difference in uptake of the drugs occurs. Other possibilities, such as differences in affinities to metabolic enzyme or glutathion, and differences in efflux from the cell, cannot be ruled out. Further studies regarding the molecular mechanisms are needed to exactly explain the difference of nephrotoxicity between the isomers.
With respect to DWA21 14R, the results in this study revealed that DWA21 14R exhibited equivalent or greater antitumor activity compared with carboplatin, and no nephrotoxicity, unlike cisplatin. These results suggest that DWA-2114R could be a promising new platinum anticancer agent.
